Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oramed Pharmaceuticals (ORMP) Net Margin (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Net Margin for 3 consecutive years, with 3526.44% as the latest value for Q2 2024.

  • For the quarter ending Q2 2024, Net Margin fell 296397.0% year-over-year to 3526.44%, compared with a TTM value of 1514.07% through Dec 2024, up 130317.0%, and an annual FY2024 reading of 1971.51%, up 159181.0% over the prior year.
  • Net Margin was 3526.44% for Q2 2024 at Oramed Pharmaceuticals, down from 259.12% in the prior quarter.
  • Across five years, Net Margin topped out at 259.12% in Q1 2024 and bottomed at 3526.44% in Q2 2024.
  • Average Net Margin over 3 years is 1288.97%, with a median of 1162.95% recorded in 2022.
  • The sharpest move saw Net Margin soared 105556bps in 2023, then plummeted -296397bps in 2024.
  • Year by year, Net Margin stood at 1290.71% in 2022, then soared by 56bps to 562.46% in 2023, then tumbled by -527bps to 3526.44% in 2024.
  • Business Quant data shows Net Margin for ORMP at 3526.44% in Q2 2024, 259.12% in Q1 2024, and 562.46% in Q2 2023.